Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label,Sequential,Single-site Study to Evaluate the Pharmacokinetics of Warfarin When Coadministered With Polyethylene Glycol Loxenatide (PEX168) in Healthy Adult Subjects

Next Previous
Trial Profile

An Open-label,Sequential,Single-site Study to Evaluate the Pharmacokinetics of Warfarin When Coadministered With Polyethylene Glycol Loxenatide (PEX168) in Healthy Adult Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 26 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegloxenatide (Primary) ; Warfarin
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Jiangsu Hansoh Pharmaceutical

Most Recent Events

  • 26 Aug 2024 New source identified and integrated (China Drug Trials: CTR20150335).
  • 09 Mar 2018 According to ChiCTR1800015049 source this study has case series and observational design keywords. I have not updated this information since this is a phase I open label study in healthy volunteers.
  • 23 Jan 2017 Status changed from not yet recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top